Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment

Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):675-97. doi: 10.1016/j.bpg.2005.05.009.

Abstract

Duodenal neuroendocrine tumors (NETs) comprise 2-3% of all GI endocrine tumors and are increasing in frequency. These include gastrinomas, somatostatinomas, nonfunctional NETs, gangliocytic paragangliomas, and poorly differentiated NE carcinomas. Although, the majority are nonfunctional, these tumors are a frequent cause of Zollinger-Ellison syndrome and can cause other clinical hormonal syndromes (carcinoid, Cushing's, etc.). In this chapter, their epidemiology, clinical aspects, localization, diagnosis and medical treatment are reviewed including the latest advances in each area.

Publication types

  • Review

MeSH terms

  • Adult
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Biopsy, Needle
  • Carcinoid Tumor / classification
  • Carcinoid Tumor / epidemiology
  • Carcinoid Tumor / therapy*
  • Combined Modality Therapy
  • Duodenal Neoplasms / classification*
  • Duodenal Neoplasms / epidemiology*
  • Duodenal Neoplasms / therapy
  • Duodenoscopy / methods
  • Female
  • Humans
  • Immunohistochemistry
  • Incidence
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neuroendocrine Tumors / classification*
  • Neuroendocrine Tumors / epidemiology*
  • Neuroendocrine Tumors / therapy
  • Prognosis
  • Risk Assessment
  • Sex Distribution
  • Somatostatinoma / classification
  • Somatostatinoma / epidemiology
  • Somatostatinoma / therapy
  • Survival Analysis
  • United States / epidemiology
  • Zollinger-Ellison Syndrome / classification
  • Zollinger-Ellison Syndrome / epidemiology
  • Zollinger-Ellison Syndrome / therapy